Results 51 to 60 of about 10,714 (176)
Clinical and Translational MedicineBackground Most gastrointestinal stromal tumours (GISTs) are driven by KIT proto‐oncogene, receptor tyrosine kinase (KIT). Targeted treatment with imatinib has been successful in primary GIST patients.
Chunxiao He +9 more
doaj +1 more source
Compartmentalisation in cAMP signalling: A phase separation perspective
British Journal of Pharmacology, EarlyView.Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley +1 more source
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy
Annual Review of Cancer BiologyThe nonreceptor tyrosine phosphatase SHP2 has been at the center of cell signaling research for three decades. SHP2 is required to fully activate the RTK/RAS/ERK signaling cascade, although the underlying mechanisms are not completely understood.
Scheiter, Alexander +3 more
openaire +3 more sources
New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer
Cancer Science, EarlyView.Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi +2 more
wiley +1 more source
A Noncanonical Protein Degradation Pathway That Regulates Germ Cell Maintenance
Cell Proliferation, EarlyView.SENP8 regulates a non‐canonical NEDD8‐dependent pathway to stabilize STAT1, promote CCL2/CCL5 transcription, and maintain germ cell proliferation and migration.
Meng Liu +11 more
wiley +1 more source
Biopolymers, Volume 117, Issue 5, September 2026.The two phosphorylation sites within the Gab1 fragment 142‐203 exhibit distinct structural characteristics. Tyr162 is in a disordered region, Y183 in a helical segment. ABSTRACT The biological function of intrinsically disordered proteins is frequently coupled to short linear motifs, which serve as protein binding sites.
Anne Dietrich +5 more
wiley +1 more source
Nature Communications, 2021 SHP2 promotes RAS-driven MAPK signalling, but it is unclear why cancer cells with distinct KRAS mutations exhibit differential sensitivity to SHP2 inhibition. Here the authors show that KRAS Q61H is decoupled from SHP2- mediated upstream regulation, thus
Teklab Gebregiworgis +21 more
doaj +1 more source
Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors [PDF]
Oncotarget, 2023 Franciosa, Giulia, Olsen, Jesper V
openaire +3 more sources
Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
Oncotarget, 2012 Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders which result in enhanced production of immature and mature myeloid lineage-derived cells. Included in this category are the non-classical MPNs, systemic mastocytosis (SM) and juvenile myelomonocytic leukemia (JMML)[1].
Raghuveer Singh, Mali +2 more
openaire +3 more sources